
Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion…
Read moreNews & Views
Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion…
Read moreTelix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT…
Read moreTelix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal cancer imaging product…
Read moreTelix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in…
Read moreTelix Pharmaceuticals Limited has today announced that Group CBO Dr. David Cade presented at Jefferies Virtual Healthcare…
Read moreNews,
Telix Pharmaceuticals announces that Dr Colin Hayward has joined Telix’s executive leadership team in the role of Chief Medical Officer…
Read moreTelix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29…
Read moreTelix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings…
Read moreTelix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for…
Read moreTelix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of…
Read more